Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene's Q2 Sales Decline as Litigation Charge Turns Profit to Loss

NEW YORK (GenomeWeb News) — Stratagene today reported a slight drop in second-quarter earnings while a litigation-related charge caused net income to swing to a loss.
 
Total receipts for the three months ended June 30 were down 6 percent to $23.4 million from $24.9 million year over year.
 
The company attributed the decline to poor sales of its gene-discovery and cloning systems products. Stratagene noted that sales of its QPCR instruments and its allergy diagnostic products were up 3.5 percent and 2.5 percent, respectively, year over year.
 
Stratagene posted a net loss of $3.7 million for the quarter compared to a net income of $2.1 million in Q2 2005. The company said the loss reflected a $7.9-million litigation charge related to a July jury verdict that found it guilty of infringing certain of Invitrogen's patents.
 
Meantime, R&D spending grew 8.6 percent to $3.1 million for the quarter from $2.9 million in the prior-year period. The company said the increase was due to instrument and pathway analysis software development costs.
 
As of June 30, Stratagene had $33.6 million in cash and cash equivalents.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.